Study of the Orsiro Drug Eluting Stent System
Launched by BIOTRONIK AG · May 19, 2011
Trial Information
Current as of June 08, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Main Inclusion Criteria:
- • Subject has provided a written informed consent
- • Single de novo lesion with ≥ 50% and \<100% stenosis in up to 2 coronary arteries
- • The target lesion length is ≤ 26 mm
- • The target reference vessel diameter is ≥ 2.25 mm and ≤ 4.0 mm
- Main Exclusion Criteria:
- • Evidence of myocardial infarction within 72 hours prior to index procedure
- • Unprotected left main coronary artery disease (stenosis \>50%)
- • Three-vessel coronary artery disease at time of procedure Thrombus in target vessel
- • Target lesion involves a side branch \> 2.0 mm in diameter
- • Heavily calcified lesion
- • Target lesion is located in or supplied by an arterial or venous bypass graft
About Biotronik Ag
Biotronik AG is a leading global medical technology company, headquartered in Berlin, Germany, specializing in innovative cardiovascular and endovascular solutions. With a strong commitment to advancing patient care, Biotronik develops cutting-edge devices and therapies that enhance the diagnosis and treatment of cardiovascular diseases. The company's extensive portfolio includes implantable cardiac devices, vascular interventions, and remote patient monitoring systems, all designed to improve clinical outcomes and quality of life. Biotronik AG is dedicated to rigorous clinical research and collaboration with healthcare professionals, ensuring the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Bad Segeberg, , Germany
Nuernberg, , Germany
Berlin, , Germany
Geneva, , Switzerland
Sevilla, , Spain
Wels, Oberoesterreich, Austria
Massy, , France
Montpellier, , France
Ollioules, , France
Bad Krozingen, , Germany
Bad Oeyenhausen, , Germany
Lübeck, , Germany
Neuss, , Germany
Rostock, , Germany
Budapest, , Hungary
Riga, , Latvia
Amsterdam, , Netherlands
Barcelona, , Spain
Madrid, , Spain
Lugano, Tessin, Switzerland
Bern, , Switzerland
Fribourg, , Switzerland
Lucerne, , Switzerland
Patients applied
Trial Officials
Stephan Windecker, MD
Principal Investigator
University Hospital (Inselspital) / Bern / Switzerland
Thierry Lefèvre, MD
Principal Investigator
Institute Hospitalier Jaques Cartier / Massy / France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials